Ovoca Bio Plc Logo

Ovoca Bio Plc

Biopharma developing a novel therapy for premenopausal women with low sexual desire (HSDD).

OVXA | IR

Overview

Corporate Details

ISIN(s):
IE0006649010 (+1 more)
LEI:
213800ST2AK5XQ1O5207
Country:
Ireland
Address:
17 PEMBROKE STREET UPPER, D02 AT22 DUBLIN
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ovoca Bio Plc is a clinical-stage biopharmaceutical company focused on developing novel treatments for women's health. The company's lead product candidate is Orenetide, a medicinal therapy for premenopausal women with hypoactive sexual desire disorder (HSDD), a condition with significant unmet medical need. Ovoca Bio is advancing Orenetide through clinical development and regulatory approval processes in the US, Europe, and other major global markets. The company's strategy involves leveraging its protective patent portfolio and seeking commercialization through licensing agreements and collaborations with pharmaceutical partners.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-30 14:09
Report Publication Announcement
Replacement Half Year Report
English 10.8 KB
2025-06-05 08:00
Delisting Announcement
Delisting from Euronext Growth Exchange
English 9.0 KB
2025-03-03 15:00
Board/Management Information
Management Changes
English 8.0 KB
2024-12-18 19:00
Post-Annual General Meeting Information
Result of AGM
English 7.1 KB
2024-11-18 08:00
Pre-Annual General Meeting Information
Notice of AGM
English 7.0 KB
2024-10-11 18:30
Major Shareholding Notification
Holding(s) in Company
English 6.8 KB
2024-10-09 18:45
Transaction in Own Shares
Sale of Treasury Shares
English 6.0 KB
2024-09-25 08:00
Report Publication Announcement
Half-year Report
English 7.6 KB
2024-09-02 15:30
Related Party Transaction
Consultancy Agreement
English 8.7 KB
2024-07-15 08:00
Director's Dealing
Director/PDMR Shareholding
English 27.4 KB
2024-07-15 08:00
Board/Management Information
Directorate Change
English 8.8 KB
2024-06-28 08:00
Report Publication Announcement
Annual Financial Report
English 14.5 KB
2024-06-20 00:00
Annual Report
English 1.2 MB
2024-01-23 08:00
Major Shareholding Notification
Holding(s) in Company
English 7.9 KB
2023-12-01 13:00
Post-Annual General Meeting Information
Result of AGM
English 7.8 KB

Automate Your Workflow. Get a real-time feed of all Ovoca Bio Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ovoca Bio Plc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ovoca Bio Plc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Fine Foods & Pharmaceuticals Ntm Logo
Contract development & manufacturing of oral solids for pharma, nutraceutical & cosmetic sectors.
Italy FF
Formycon AG Logo
Develops cost-effective biosimilars for ophthalmology, immunology, and other chronic diseases.
Germany FYB
Friulchem Logo
CDMO for animal health, providing vet pharma & supplement solutions for pets and livestock.
Italy FCM
Fuji Pharma Co.,Ltd. Logo
Specializes in hormone medicines for ob/gyn, injectables, and contract manufacturing.
Japan 4554
Fuso Pharmaceutical Industries,Ltd. Logo
Manufactures essential pharmaceuticals like dialysis drugs, infusions, and injections for healthcare.
Japan 4538
FutureChem Co., Ltd. Logo
Develops radiopharmaceuticals & diagnostic agents for cancer, Alzheimer's, and Parkinson's disease.
South Korea 220100
Future Medicine  Co., Ltd. Logo
Clinical-stage biopharma developing novel synthetic drugs for inflammation, fibrosis, and oncology.
South Korea 341170
Develops long-acting injectable therapies for chronic diseases and cancer.
South Korea 456160
Gabather AB Logo
Developing novel GABAA receptor drugs for neuropsychiatric disorders.
Sweden GABA
Galapagos NV Logo
Biotech firm developing novel CAR-T cell therapies for oncology via a rapid delivery platform.
Belgium GLPG

Talk to a Data Expert

Have a question? We'll get back to you promptly.